Kailera Therapeutics raised $718 million in its April 2026 IPO to develop GLP-1 drugs for obesity treatment. Its lead candidate, ribupatide, demonstrated a strong weight loss effect (23.6% at 36 weeks) and good safety in studies outside China. Although the stock price fell 40% post-IPO, the company's $1.65 billion valuation and $900 million cash reserve make it attractive. Key milestones are expected in 2027-2028 with pivotal trial data, but success depends on replicating Chinese trial results in the U.S.
Kailera Therapeutics, noted for its $1.65 billion valuation and $900 million cash reserve after its April 2026 IPO, is developing GLP-1 drugs for obesity. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 22:21 WIB: Among 91 priced US health stocks, 65 rose and 25 fell. Notable movers include RXRX at USD 3.53 (+10.66%, 22 days typical hold time, 0% sell / 100% buy), BNGO at USD 1.67 (+10.60%, 49 days typical hold time, 77% sell / 23% buy), and ABCL at USD 12.90 (+10.54%, 40 days typical hold time, 99% sell / 1% buy).
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...
Analyst Ivan Feinseth of Tigress Financial raised Amazon's price target from $315 to $385, reflecting a potential 50.8% upside from the current price of $255.37. The upgrade is driven by strong demand for Amazon Web Services (AWS), with much of its 2...
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
